Boston Scientific Corporation has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical device company focused on therapies for bladder dysfunction. The acquisition strengthens Boston Scientifi..
Alembic Pharmaceuticals has clinched tentative approval from the US Food & Drug Administration (USFDA) for its Bosutinib Tablets, 400?mg — a major generic cancer drug move that expands its foothold in the lucrative US oncology market...
Bristol Myers Squibb today reported positive Phase 3 results for Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The data come from the Phase 3 SCOUT-HCM trial, the first study of a cardiac myosin inhibitor...
Eli Lilly and Company announced today a major partnership with NVIDIA to launch a first-of-its-kind AI co-innovation lab designed to take on some of the pharmaceutical industry’s hardest problems. The collaboration will see the two companies...
AbbVie and RemeGen have entered into an exclusive global licensing agreement to develop and commercialise RC148, an investigational bispecific antibody for cancer treatment. Under the agreement, AbbVie will hold rights to RC148 outside Greater Ch...
Metropolis Healthcare launches Centre of Genomics, offering advanced sequencing, precision medicine, AI-driven insights, and clinically integrated genomic diagnostics in India.
Jubilant Biosys opens new Noida facility, doubling chemistry capacity for discovery and scale-up, offering FFS contracts, pilot plants, and end-to-end drug discovery solutions.
.jpeg "Aragen Launches CHOMax for Fast DNA to IND Clinical Supply")
Aragen launches CHOMax, a cell line and early manufacturing platform, taking monoclonal antibody programmes from DNA to IND-enabling clinical supply in 10 months.
Novartis to build its fourth US radioligand therapy facility in Florida, boosting RLT supply, ensuring timely cancer treatment, and expanding its $23 billion US investment.
Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration for its supplemental Abbreviated New Drug Application (sANDA) for Bosutinib tablets, 400 mg, strengthening the company’s US oncology generics market pre...
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")